Nuvilex Inc (NVLX) 0.1918 $NVLX Pharmacyte Biotech

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Nuvilex Inc (NVLX) 0.1918 $NVLX

Pharmacyte Biotech Experiencing Marginal Success Still has Several Challenges in Coming Year: Analyst Report Issued by BrokerBank Securities, Inc.
PR Newswire - Fri Jan 09, 6:00AM CST
PharmaCyte Biotech (OTCQB: PHCB) formerly, Nuvilex Inc. (OTCQB: NVLX) as of January 8th, 2015, based out of Silver Spring, Maryland, is a biotechnology firm leveraging its proprietary Cell-in-a-Box® to usher in new approaches to the treatment and management of several forms of cancer. The recent name change is to highlight the shift that PharmaCyte Biotech will now be operating as a purely biotechnology firm.

Advanced Cultivation Technologies for Legal Marijuana & Cannabis Growers Impact Growth of Expanding Cannabis Industry
PR Newswire - Thu Jan 08, 7:45AM CST
Company Acquires Majority Interest in Leading Cannabis Seed-to-Sale Tracking Platform And Receives Coverage in New Analyst Report

Cannabis Industry & Legal Marijuana Opportunities Become Hot Topic for 2015 as Product Commercialization Programs Improve Cultivation Operations
PR Newswire - Tue Jan 06, 7:45AM CST
As more and more medical marijuana dispensaries open in approved states, Cannabis/Marijuana Companies and Providers look for improved technology for innovative methods that address the energy and resources for intensive nature of indoor/outdoor cannabis cultivation. Companies in focus today are: Surna Inc. (OTC: SRNA), Cannabis Science, Inc. (OTC: CBIS), Nuvilex, Inc. (OTC: NVLX), GW Pharmaceuticals plc (NASDAQ: GWPH) and Easton Pharmaceuticals Inc. (OTC: EAPH) and Terra Tech Corp (OTC: TRTC).
GWPH: 84.16 (+2.78)

FDA Grants Orphan Drug Designation to Nuvilex for Pancreatic Cancer Treatment
GlobeNewswire - Mon Dec 22, 7:40AM CST
Nuvilex, Inc. (OTCQB:NVLX), a clinical-stage biotechnology company providing cell therapy solutions for the treatment of diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Nuvilex orphan drug designation for its pancreatic cancer treatment. Nuvilex's pancreatic cancer treatment combines Nuvilex's patented and proprietary cellulose-based encapsulation technology, known as Cell-in-a-Box, with the cancer prodrug ifosfamide and encapsulated live cells that convert the prodrug into its cancer-killing form. These capsules are placed as close to the cancerous tumor as possible to enable the delivery of the highest levels of the cancer-killing drug at the source of the cancer. This "targeted chemotherapy" has proven remarkably effective in past clinical trials.

Nuvilex's Partner Austrianova Successfully Completes First Live Cell Encapsulation in New Facility
GlobeNewswire - Thu Dec 18, 11:56AM CST
Nuvilex, Inc. (OTCQB:NVLX), a clinical-stage biotechnology company providing cell and gene therapy solutions for the treatment of diseases, today announced that its partner, Austrianova, successfully completed the first live cell encapsulation at Austrianova's new facility in the Thai Science Park in Bangkok, Thailand. This is an important milestone in assuring the facility is compliant with the current Good Manufacturing Practices (cGMP) and that the encapsulation of the cancer prodrug-activating cells used in the Cell-in-a-Box technology platform, as part of Nuvilex's pancreatic cancer treatment, will be fully functional.

Nuvilex Provides Shareholder Update on Cancer and Diabetes Programs
GlobeNewswire - Tue Dec 16, 8:30AM CST
Nuvilex, Inc. (OTCQB:NVLX), a clinical-stage biotechnology company providing cell solutions for the treatment of diseases, today announced a shareholder update on the Company's cancer and diabetes programs utilizing its Cell-in-a-Box cellulose-based live cell encapsulation technology.

Nuvilex Provides Update on Significance of Austrianova's cGMP Live-Cell Encapsulation Facility
GlobeNewswire - Wed Dec 10, 8:30AM CST
Nuvilex, Inc. (OTCQB:NVLX), a clinical-stage biotechnology company providing cell therapy solutions for the treatment of diseases, is pleased to provide an update on the significance of its partner, Austrianova, opening a new, state-of-the-art current Good Manufacturing Practices (cGMP)-compliant live-cell encapsulation facility inside the Thailand Science Park (TSP). This facility will produce the Cell-in-a-Box live-cell encapsulation product that will be the centerpiece for all of Nuvilex's treatments in human clinical trials.

Nuvilex Announces Name Change of Subsidiary to Viridis Biotech
GlobeNewswire - Mon Dec 08, 9:15AM CST
Nuvilex, Inc. (OTCQB:NVLX), a preclinical and clinical-stage biotechnology company providing cell therapy solutions for the treatment of diseases, announced today that it has changed the name of its subsidiary, Medical Marijuana Sciences, Inc., to Viridis Biotech, Inc. This name change is part of Nuvilex's continuing process to make changes at Nuvilex that better reflect its role as a biotechnology company and to strengthen the Nuvilex brand.

Nuvilex Announces the Opening of Austrianova's cGMP Live Cell Encapsulation Facility in Thailand
GlobeNewswire - Thu Dec 04, 8:44AM CST
Nuvilex, Inc. (OTCQB:NVLX), a clinical-stage biotechnology company providing cell therapy solutions for the treatment of diseases, announced today that Nuvilex executives joined Thailand government officials at the grand opening of Austrianova's current Good Manufacturing Practices (cGMP) live-cell encapsulation facility within the Thai Science Park (TSP) in Bangkok, Thailand. The TSP is the premier Science, Technology and Innovation hub of Thailand and home to many leading international hi-tech and bio-tech companies.

Nuvilex Obtains Exclusive Worldwide License to Develop Disease Treatments That Combine Cell-in-a-Box(R) and Cannabinoid-Based Medicine
GlobeNewswire - Mon Dec 01, 8:30AM CST
Nuvilex, Inc. (OTCQB:NVLX), a clinical-stage biotechnology company developing cell therapy solutions for the treatment of diseases, announced today that it has obtained an exclusive worldwide license from Austrianova Singapore Pte Ltd to use the unique and proprietary Cell-in-a-Box cellulose-based live cell encapsulation technology in combination with compounds, known as cannabinoids, obtained from constituents of Cannabis for the development of disease treatments. Nuvilex's initial efforts will be directed toward developing treatments for deadly and difficult-to-treat forms of cancer.

Legal Marijuana Industry Outlook Positive As Advanced Technologies & Socially Acceptable Cannabis Products Lead to Increased Revenues
PR Newswire - Mon Nov 24, 9:57AM CST
Legal Marijuana & Cannabis Industry lean more toward heavily capitalized investors as Leading Technology & MMJ Manufacturers set sights on the Mainstream and becoming more socially acceptable. Major MMJ Companies in focus today are: Surna Inc. (OTC: SRNA), Medical Marijuana Inc. (OTC: MJNA), Hemp, Inc. (OTC: HEMP), Cannabis Science, Inc. (OTC: CBIS) and Nuvilex, Inc. (OTC: NVLX)

Nuvilex Announces the Formation of a Diabetes Consortium for the Development of Its Treatment for Insulin-Dependent Diabetes
GlobeNewswire - Mon Nov 24, 7:30AM CST
Nuvilex, Inc. (OTCQB:NVLX), a clinical-stage biotechnology company providing cell therapy solutions for the treatment of diseases, announced today that it has formed a "Diabetes Consortium" that will be tasked with the development of Nuvilex's treatment for insulin-dependent diabetes.

Nuvilex Executives in Southeast Asia to Further Advance Cell-in-a-Box Technology(R)
GlobeNewswire - Fri Nov 21, 8:36AM CST
Nuvilex, Inc. (OTCQB:NVLX), a clinical-stage biotechnology company providing cell therapy solutions for the treatment of diseases, announced today Nuvilex's Chief Executive Officer, Kenneth L. Waggoner, and Chief Operating Officer, Gerald W. Crabtree, Ph.D., are in Singapore to finalize the Diabetes Consortium that will develop a treatment for insulin dependent diabetes, to negotiate an additional worldwide, exclusive license to use Cell-in-a-Boxlive cell encapsulation with cannabinoids to treat diseases and related symptoms and to tour the new facilities of Austrianova in Singapore. Mr. Waggoner and Dr. Crabtree will also be attending the grand opening of the cGMP (current Good Manufacturing Practices) facility in Thailand where the cells required for Nuvilex's preclinical and clinical trials will be encapsulated using the Cell-in-a-Box technology.

Nuvilex Announces Preliminary Data From Preclinical Study of Effects of Its Pancreatic Cancer Treatment on Ascites Fluid Formation
GlobeNewswire - Wed Nov 19, 9:33AM CST
Nuvilex, Inc. (OTCQB:NVLX), a clinical-stage biotechnology company providing cell therapy solutions for the treatment of diseases, announced today that promising preliminary data has been released from the preclinical animal study on the effects of Nuvilex's pancreatic cancer treatment on the accumulation of ascites fluid in tumor-bearing animals. This study, performed by Nuvilex contractor, Translational Drug Development (TD2), employed immunosuppressed mice implanted with disseminated human ovarian cancer cells into the peritoneal cavity.

Nuvilex Applies in Australia for the Orphan Drug Designation for Pancreatic Cancer Treatment
GlobeNewswire - Fri Nov 07, 8:35AM CST
Nuvilex, Inc. (OTCQB:NVLX), a clinical-stage biotechnology company providing cell and gene therapy solutions for the treatment of diseases, announced today that it has submitted, through its subsidiary Nuvilex Australia, an application to the Therapeutic Goods Administration (TGA) in Australia to obtain the Orphan Drug Designation for its pancreatic cancer treatment. This submission follows similar applications to the United States Food and Drug Administration and the European Medicines Agency in the European Union (EU). Like those in the U.S. (7 years) and the EU (10 years), granting of the Orphan Drug Designation carries with it a significant period of marketing exclusivity. In Australia this period is 5 years.

Breakthrough Diabetes Research to Be Commercialized by US-Based Nuvilex, Inc.
Marketwired - Mon Nov 03, 9:49AM CST
Australian research that has produced a line of insulin producing cells that could eliminate the need for injections for Type 1 diabetics will be commercialized by US company Nuvilex, Inc. (OTCQB: NVLX) and its subsidiaries Nuvilex Australia and Nuvilex Europe.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Clinch Scores Big with Two Prestigious Industry Honors

Updated Category News Views 39

Clinch's Dual Triumph in Advertising Innovation No one throws a ticker symbol over their cereal for recognizing brilliance, but when an outfit like Clinch gets double applause at the big dance, even we old-timers have to tip our hats. On November 16, 2026, the advertising world saw some fireworks. Clinch took home not one but two hefty awards—the kind that say you've...

Continue Reading
Atomera Preps for Key Craig-Hallum Conference

Updated Category News Views 59

Unpacking the NYC Gathering Alight, let's comb through the moving parts here. Atomera Inc., ticker NASDAQ: ATOM for those eyeing the dance of numbers, is all set to step into the limelight at the 17th Annual Craig-Hallum Alpha Select Conference on November 17, 2026. This shindig isn't just another date on the calendar; it's a strategic haunt where Atomera will rub...

Continue Reading
Mercari and Suruga-ya Forge U.S. Venture for Culture

Updated Category News Views 141

Japanese Pop Culture Gears Up for US Market Surge Alright, folks, what we’ve got here is another bold move in the cross-border e-commerce game. Mercari and Suruga-ya are teaming up to establish a joint venture over in the U.S. The goal? To further capitalize on the growing appetite for Japanese entertainment and hobby goods among us all stateside. Now, it’s no secret...

Continue Reading
Hanwha Power Seals Second FSRU Conversion Deal

Updated Category News Views 168

Riding the FSRU Wave with Hanwha Power Alright, we've got Hanwha Power step-dancing onto the LNG stage with its second splash into the FSRU (Floating Storage and Regasification Unit) conversion gig. Partnering up with Energos Infrastructure, these guys are making serious waves in the energy market by transforming what's pretty much a regular ship into a floating gas...

Continue Reading
Bank Hapoalim's Q3 2026: Steady Growth Amid Challenges

Updated Category News Views 105

Digging Deep into Hapoalim's Recent Results Now ain't this a turn of events? Bank Hapoalim rolls out its numbers for Q3 2026, and while there's no confetti dropping from the ceiling, the numbers are telling their own story. Net profit comes to a solid NIS 2,364 million, but we're looking at a landscape that's not all rose-tinted today. The bank's managed to pull off...

Continue Reading
Ozelle Unveils AI-Powered Hematology Tool at MEDICA 2026

Updated Category News Views 116

Pioneering a New Era in Hematology In the fast-paced world of blood analysis, standing still means being left in the dust. Ozelle, with its AI-powered innovative tool, is making waves at MEDICA 2026 in Düsseldorf. Meet O-Cyte 1, an automated hematology analyzer that's merging high-resolution cell imaging with routine CBC (Complete Blood Count) testing. Sounds like...

Continue Reading
Ranger and Smith Unveil Tea-Infused Chocolate Bar

Updated Category News Views 11

Fresh Collaborations in Portland's Culinary Scene Ah, the sweet crossover in Portland's food scene is once again in the spotlight with a new entry that's sure to titillate taste buds. Ranger Chocolate Co. and Steven Smith Teamaker are at it again, rolling out a delectable creation that merges the poetic elegance of tea with the indulgent richness of chocolate. Welcome,...

Continue Reading
Cargo Drones to Skyrocket with $9.14B Value by 2031

Updated Category News Views 58

Riding the Drone Wave I tell you what, folks, the whole business of cargo drones is getting frickin' interesting. These flying gizmos, once dismissed as science fiction, are now barging their way into logistics discussions like an uninvited guest who's too worthwhile to ignore. MarketsandMarkets™ reckons this market's about to smash through the $9 billion ceiling by...

Continue Reading
HearUSA Expands Access with AI-Powered Hearing Aids

Updated Category News Views 74

AI Revolution in Hearing Care Look, the hearing aid industry isn't known for headlines that grab you by the throat, but HearUSA just tossed a proverbial grenade into the scene with Widex Allure AI RIC. This is more than a slight tweak in hearing tech—it's a game-changer. We're talking about on-demand AI noise management blended with Widex's renowned natural sound. It's...

Continue Reading
Bizzdesign Tops Gartner’s 2026 Enterprise Architecture List

Updated Category News Views 100

Enterprise Architecture’s Silent Backbone Sometimes it's the quiet operators like Bizzdesign that hijack the spotlight after years of steady steering. With the latest nod from Gartner, Bizzdesign is clearly on a tear in the enterprise architecture domain. In their 2026 Critical Capabilities report, Bizzdesign's products—Horizzon, Alfabet, and Hopex—secured top spots...

Continue Reading

Top 5 Most Recently Viewed Articles

Projected Growth of the Fast Food Sector through 2029

Updated Category News Views 169

Overview of Fast Food Market Growth The fast food industry is on the cusp of significant transformation, projected to grow by USD 119.6 billion between the years 2025 and 2029. This remarkable growth is anticipated to occur at a compounded annual growth rate (CAGR) of 3%. Companies in the fast food sector are increasingly recognizing the need to enhance their online...

Continue Reading
Clean Cooking Accelerator: Africa's Energy Gamble Unveiled

Updated Category News Views 200

Feb 18, 2026, saw a significant move during the International Energy Agency's Ministerial as the Clean Cooking Accelerator Initiative was unveiled. Launched by powerhouses like The Rockefeller Foundation and Global Energy Alliance, this initiative is aiming for a seismic shift in how nearly one billion Africans cook daily—traditionally relying on wood and charcoal....

Continue Reading
Volta Finance Limited: Monthly Insights and Performance Metrics

Updated Category News Views 252

Understanding Volta Finance Limited's Performance for September 2025 Volta Finance Limited (VTA / VTAS) recently released its monthly report for September 2025. This report sheds light on the performance metrics that have shaped the company's strategies and outcomes over the past month, illustrating how they navigate an ever-changing financial landscape. Performance...

Continue Reading
AutoFull's Massage Gaming Chair Powers Esports

Updated Category News Views 36

Innovation Meets Gaming at IEM Cologne 2026 Nobody expected gaming chairs to steal the spotlight at the IEM Cologne Major 2026, but AutoFull had other plans. By rolling out their blazing new pieces of gaming tech, they're not just a sponsor — they're part of the competitive edge. Setting the Stage at a Competitive Colosseum Team FALCONS may have walked away with the...

Continue Reading
IBM's Nickle LaMoreaux Earns Prestigious HR Executive Title

Updated Category News Views 114

Nickle LaMoreaux Recognized as 2024 HR Executive of the Year WEST PALM BEACH, Fla. and BOSTON - In a significant announcement from HR Executive™, Nickle LaMoreaux, serving as Senior Vice President and Chief Human Resources Officer at IBM, has been honored as the 2024 HR Executive of the Year. This distinguished recognition reflects her exceptional contributions to the...

Continue Reading